Yumiko Azuma

ORCID: 0009-0007-1657-434X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Research Studies
  • CAR-T cell therapy research
  • Cancer therapeutics and mechanisms
  • Immunotherapy and Immune Responses
  • Biochemical Analysis and Sensing Techniques
  • Regulation of Appetite and Obesity
  • Bone health and treatments
  • Bone Metabolism and Diseases
  • Parathyroid Disorders and Treatments
  • Sleep and Wakefulness Research

Abstract Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The was competitively...

10.1158/2326-6066.cir-23-0638 article EN Cancer Immunology Research 2024-04-01

Abstract Purpose: Parathyroid hormone-related protein (PTHrP) is a causative factor of humoral hypercalcemia malignancy (HHM) and concurrent anorexia wasting. Because changes in the expression hypothalamic feeding-regulating peptides can directly affect appetites thereby cause wasting, we addressed whether cachectic syndromes induced by PTHrP rely on action peptides. Experimental Design: Rats were inoculated with LC-6 human cancer xenograft that secreted PTHrP, mRNA levels peptide genes...

10.1158/1078-0432.ccr-06-1487 article EN Clinical Cancer Research 2007-01-01

Abstract Purpose: Bisphosphonate and calcitonin lower blood calcium in humoral hypercalcemia of malignancy (HHM) by suppressing osteoclastic bone resorption, but repeated administration these drugs often leads to relapse. In this study, we examined the roles parathyroid hormone–related protein (PTHrP) development bisphosphonate- calcitonin-refractory HHM. Experimental Design: Nude rats bearing LC-6 JCK tumor xenograft (LC-6 rats) exhibited high turnover Repeated alendronate induced a...

10.1158/1078-0432.ccr-04-2531 article EN Clinical Cancer Research 2005-06-01

<div>Abstract<p>Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The...

10.1158/2326-6066.c.7267968 preprint EN 2024-06-04

<div>Abstract<p>Small-cell lung cancer (SCLC) is an aggressive for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives ICI-resistant tumors, but not all patients with SCLC responsive. Herein, to integrate CD137 costimulatory function into a engager format and thereby augment efficacy, we generated CD3/CD137 dual-specific Fab engineered DLL3-targeted trispecific antibody (DLL3 trispecific). The...

10.1158/2326-6066.c.7267968.v1 preprint EN 2024-06-04
Coming Soon ...